INDP
Indaptus TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is mostly optionality: if management secures fresh capital on tolerable terms and can point to a credible funded development path for Decoy20, the stock could re-rate sharply from a depressed base.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Balance-sheet and runway risk remain acute: the company reported roughly $1.5 million of cash at March 31, 2026 and expected funding only through Q2 2026 [#10-Q-2026-05-15].
Momentum
88
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.50 · Bear $0.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum88 · Δ7d -
Value42 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-17.4
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 88.5 / Value 41.9 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$217.43M
Beta
0.99
Shares Out
1.75M
P/E (TTM) · Derived
-2.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.09
Rev YoY
-
EPS YoY
+67.0%
Gross Margin
-
Op Margin
-
Net Debt
-$5.79M
Current Ratio
2.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology